Menu Search
Charts
From 02/05/2022 our Markets Data content will no longer be free to read. To continue to get full access, subscribe now and receive 25% off.
Learn moreSubscribe now
Equities

Novartis AG

NOTA:DUS

Novartis AG

Actions
  • Price (EUR)99.60
  • Today's Change-1.40 / -1.39%
  • Shares traded120.00
  • 1 Year change+13.70%
  • Beta--
Data delayed at least 15 minutes, as of Oct 31 2024 18:31 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.

  • Revenue in USD (TTM)49.94bn
  • Net income in USD11.76bn
  • Incorporated1996
  • Employees76.06k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		NOVN:SWX since
announced		Transaction
value
IFM Due IncAnnounced13 Mar 202413 Mar 2024Announced7.09%835.00m
Cytokinetics IncRumoured08 Jan 202408 Jan 2024Rumoured3.75%--
Calypso Biotech BVAnnounced08 Jan 202408 Jan 2024Announced3.75%425.00m
SanReno TherapeuticsDeal completed05 Jan 202405 Jan 2024Deal completed4.41%--
Data delayed at least 15 minutes, as of Oct 31 2024 16:37 BST.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.